Home >
World Psoriasis Day 2019
2019/10/29
Today, IFPA presents World Psoriasis Day, as an annual day dedicated to people with psoriasis and/or psoriatic arthritis. It has been celebrated on October 29 for more than a decade. On World Psoriasis Day, our member associations and their supporters organise activities around the world to raise awareness of psoriasis.
To see examples of all the activities our members put on in around the world last World Psoriasis Day, visit worldpsoriasisday2018.com.
Aim of World Psoriasis Day
World Psoriasis Day is dedicated to people living with psoriasis or psoriatic arthritis. On October 29, we aim to address their needs:
Raise awareness
Psoriasis affects over 125 million people around the world – not just physically, but also socially, emotionally and financially. World Psoriasis Day aims to raise the profile of this debilitating disease and increase awareness of the effect it has on people’s lives.
Spread information
For many, psoriasis is still a relatively unknown disease. On World Psoriasis Day, IFPA spreads information about psoriasis, dispel common myths and answer questions. They also inform patients about their own condition, so they can feel empowered to speak about it.
Improve access to treatment
On World Psoriasis Day, IFPA lobby to give people with psoriasis better access to appropriate, affordable treatment. That’s why they specifically address key health decision-makers like national governments, policy-makers and healthcare providers that day.
Give the psoriasis community a voice
Many people living with psoriasis may struggle to get the world to listen to their needs. World Psoriasis Day is an opportunity for the psoriasis community to speak out from a common platform – and have its voice heard.
Are there special World Psoriasis Day activities?
Yes! Each year, IFPA member associations organise a wide variety of World Psoriasis Day activities – from small gatherings to large-scale events. Examples of activities include:
Awareness-raising walks or running events
Free information events for the general public
Lectures or seminars held by medical professionals
Handing out flyers and brochures in public places
Drawing competitions
Sending out WPD postcards
Free psoriasis assessment and consultations at hospitals
Activities for children and youth
Photo exhibitions with psoriasis-related themes
Radio or TV interviews with patient leaders or medical experts
Fundraising barbecues, get-togethers or concerts
Outdoor yoga sessions for people with psoriasis
Coverage of World Psoriasis Day by local or national media
Can I join World Psoriasis Day?
Of course! World Psoriasis Day is open to anyone – whether you have psoriasis yourself, know someone who does or simply want to support people living with psoriasis.
To be part of World Psoriasis Day, you can:
Contact your national psoriasis association to find out about their plans for October 29.
Organise an activity yourself. Perhaps your national association isn’t planning anything or you live in a country without an active psoriasis association? Don’t let this stop you! Organising a workshop, an awareness-raising walk, or simply handing out flyers can be a great way to let your community know about World Psoriasis Day. If you organise something, we’d love to hear about it! That way, IFPA can help promote your activity and share some pictures afterwards for our global audience.
Follow IFPA on Facebook or Twitter to get the latest updates on IFPA’s World Psoriasis Day campaigns and plans.
Spread the word about World Psoriasis Day, wear orange and blue on October 29, or reach out to someone from the psoriasis community to let them know you are there for them.
SOURCE: https://ifpa-pso.com/our-actions/world-psoriasis-day/
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
Prof Nelida Aurora Raimondo
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Total glucosides of paeony: A review of its phytochemistry, role in autoimmune diseases, and mechanisms of action.
J Ethnopharmacol.
2020 Aug 10, 258:112913.
Paeoniae Radix Alba (PRA, called baishao in China), the root of Paeonia lactiflora Pall., has shown a rich medicinal value for more than 2000 years. PRA is used in local medicine and traditional medicine for autoimmune diseases associated with inflammation. At present, total glucosides of paeony (TGP), the main active ingredient of PRA, has been developed into a preparation for the treatment of autoimmune diseases, as TGP exhibits the effect of regulating immunity, anti-inflammatory, and (...)
see on pubmed
Immobilization of papain enzyme on a hybrid support containing zinc oxide nanoparticles and chitosan for clinical applications.
Carbohydr Polym.
2020 Sep 01, 243:116498.
A new hybrid bionanomaterial composed of zinc oxide nanoparticles (ZnO NPs) and chitosan was constructed after enzymatic immobilization of papain for biomedical applications. In this work, we report the preparation and characterization steps of this bionanomaterial and its biocompatibility in vitro. The properties of the immobilized papain system were investigated by transmission electron microscopy, zeta potential, DLS, UV-vis absorption spectroscopy, FTIR spectroscopy, and X-ray (...)
see on pubmed
Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis.
Drug Deliv.
2020 Dec , 27, (1):662-680.
Psoriasis is a dermatological chronic skin condition with underlying autoimmune etiology. It deeply affects patients' quality of life. Therefore, it was an interesting target for researchers throughout the past years. Conventionally, the treatment options include anti-inflammatory agents, immune suppressants, biologic treatment, and phototherapy. Nanotechnology offers promising characteristics that allow for tailoring a drug carrier to achieve dermal targeting, improved efficacy and (...)
see on pubmed
on Atopic Dermatitis
The clinical impact of cross-reactions between allergens on allergic skin diseases.
Curr Opin Allergy Clin Immunol.
2020 Aug , 20, (4):374-380.
The route of allergen sensing via the skin appears to influence the immune system towards mounting a type 2 response, especially in genetically predisposed individuals. Allergens recognized this way may derive from microbial, animal, food, or other plant sources and trigger atopic dermatitis. Allergens can be grouped into families depending on their structure and function, harboring significant structural and sequence similarities. Cross-reactivity between allergens is believed to arise as (...)
see on pubmed
Spectral diagnosis of health hazardous toxins in face foundation powders using laser induced breakdown spectroscopy and inductively coupled plasma-optical emission spectroscopy (ICP-OES).
Talanta.
2020 Sep 01, 217:121007.
In this work, we applied laser-induced breakdown spectroscopy (LIBS) to estimate the amount of toxic heavy metals (Pb, Cr, Ni) in five different brands of face foundation powders available in the local market using standard calibration curve (CC)-LIBS approach. These samples contain toxic elements like lead, chromium, nickel which are highly carcinogens to cause eczematous and atopic dermatitis. The strongest atomic transition lines of lead (405.7 line), chromium (425.4 nm line), and nickel (...)
see on pubmed
Update on canine filaggrin: a review.
Combarros D et al.
Update on canine filaggrin: a review.
Vet Q.
2020 Dec , 40, (1):162-168.
Human filaggrin (FLG) plays a key role in epidermal barrier function, and loss-of-function mutations of its gene are primarily responsible for the development of human atopic dermatitis (AD). FLG expression is also reduced in the epidermis of atopic patients, due to the transcriptional effect of Th2 type cytokines. Canine atopic dermatitis (CAD) is a prevalent skin disease that shares many clinical and pathogenic features with its human homologue. The aim of this review is discuss current (...)
see on pubmed
